alexa Bioequivalence and Dose Proportionality of Inhaled Fluticasone Furoate
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Bioequivalence and Dose Proportionality of Inhaled Fluticasone Furoate

Ann Allen1*, Jo Bal2, Alison Moore2, Sally Stone2 and Lee Tombs3

1Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline R&D, Stevenage, United Kingdom

2GlaxoSmithKline R&D, Stockley Park, United Kingdom

3Synergy, Slough, Berkshire, United Kingdom

*Corresponding Author:
Ann Allen
Clinical Pharmacology Modelling and Simulation
GlaxoSmithKline, Stevenage, SG1 2NY, UK
Tel: +44 1438 766350
Fax: +44 1438 764591
E-mail: ann.allen@gsk.com

Received Date: December 20, 2013; Accepted Date: January 18, 2014; Published Date: January 26, 2014

Citation: Allen A, Bal J, Moore A, Stone S, Tombs L (2014) Bioequivalence and Dose Proportionality of Inhaled Fluticasone Furoate. J Bioequiv Availab 6: 024-032. doi: 10.4172/jbb.1000176

Copyright: © 2014 Allen A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Fluticasone furoate (FF), a new inhaled corticosteroid delivered via the ELLIPTA dry powder inhaler, is being developed as a once-daily inhaled treatment for asthma. Study 1 was a part-randomised, open-label, four-way crossover, single- and repeat-dose study in healthy subjects (n=36) to assess whether the systemic exposure of FF increased proportionately across different strengths of FF (50 μg, 100 μg and 200 μg) and to determine the absolute bioavailability of FF inhalation powder. Study 2 was a randomised, open-label, replicate, six-way crossover, single-dose study in healthy subjects (n=30) to determine the bioequivalence of FF inhalation powder (single-strip configuration) compared with FF inhalation powder (two-strip configuration) and with fluticasone furoate/vilanterol (FF/VI) inhalation powder. A population pharmacokinetic analysis was also conducted on sparse samples collected
from asthma patients in five Phase III studies conducted with FF/ VI or FF.
Overall, FF systemic exposure, as measured by single-dose AUC(0-∞), was dose proportional whilst Cmax showed a less than proportional increase. Inhaled absolute bioavailability of FF was 14%. Bioequivalence was not demonstrated for FF single-strip compared with either FF two-strip or FF/VI since the estimated 90% confidence interval for the ratio of adjusted geometric means for AUC and Cmax did not fall completely between 0.8000-1.2500.
However, this difference was in line with the higher respirable mass delivered by the batch of single-strip product used in this study.
Although the formal bioequivalence study showed higher exposure with FF single-strip ELLIPTA compared with FF two-strip or FF/VI, the results of the population PK analysis of data in asthmatics show that there is no notable difference in systemic exposure between the FF configurations (single-strip, two-strip or FF/VI). In healthy subjects all treatments were generally safe and no new safety issues were apparent at these supra-therapeutic inhaled doses of FF (up to 1200 μg) and high intravenous FF dose (250 μg).

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

agriaquaculture@omicsonline.com

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

biochemjournals@omicsonline.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsonline.com

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

chemistryjournals@omicsonline.com

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

clinicaljournals@omicsonline.com

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

engineeringjournals@omicsonline.com

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

nutritionjournals@omicsonline.com

1-702-714-7001Extn: 9042

General Science

Andrea Jason

generalscience@omicsonline.com

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

geneticsmolbio@omicsonline.com

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immunomicrobiol@omicsonline.com

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

materialsci@omicsonline.com

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

nursinghealthcare@omicsonline.com

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

medicaljournals@omicsonline.com

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuropsychology@omicsonline.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

pharmajournals@omicsonline.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsonline.com

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords